Search

Displaying results 1421 - 1430 of 8575 in total
  1. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

    Products: NEGORIX ® 200MG, Dtic Dome Inj 200mg/vial
  2. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.

    Products: BEDAPT 500mg (Daptomycin for Injection 500mg per vial), Cubicin (daptomycin for injection) 500mg
  3. Drug

    Bovine type I collagen

    go.drugbank.com/drugs/DB10771
    ApprovedInvestigational

    Interestingly, bovine type I collagen has been studied as a possible endovascular stent material, and has demonstrated promising results in rabbits [A32696]. … Bovine type I collagen is also used as a health supplement for bones and joints [A32698].

  4. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].

  5. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]

  6. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  7. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

    Products: Benemid Tab 500mg, SW PROBENECID TABLET 500MG
  8. Drug

    Olive oil

    go.drugbank.com/drugs/DB09567
    ApprovedInvestigational

    Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].

  9. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  10. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.